P3‐020: AXS‐05, A NOVEL ORAL NMDA RECEPTOR ANTAGONIST WITH MULTI‐MODAL ACTIVITY IN CLINICAL DEVELOPMENT FOR AGITATION ASSOCIATED WITH ALZHEIMER'S DISEASE. (1st July 2019)